I0650-04C
Clone Type
MonoclonalHost
MouseSource
HumanConjugate
BiotinIsotype
IgG1,kClone Number
11K9Grade
PurifiedApplications
E FCCrossreactivity
HuShipping Temp
Blue IceStorage Temp
-20°CMouse Anti-ICOS Ligand (Inducible T-cell Co-stimulator Ligand, ICOSL, ICOS-L, ICOSLG, B7 Homolog 2, B7H2, B7-H2, B7-like Protein Gl50, B7-related Protein 1, B7RP1, B7RP-1, CD275, GL50, KIAA0653, LICOS) (Biotin)
The inducible costimulator CD278 (ICOS) is similar to human CD28 (24% homology), and plays an analogous role in the T cell activation process. Unlike CD28, CD278 is only expressed on activated T cells. Secondary signaling through CD28 or CD278 results in discrete cytokine secretion profiles by the activated T cells (1). Engagement of CD152 (CTLA-4) anergizes cells costimulated with either CD28 and CD278 (2). Signaling through CD278 is particularly important in progression of TH2 immune response (5). The receptor for human CD278 (ICOS) is CD275 (GL50, ICOS L), a member of the B7 family sharing ~20% homology with CD80 (B7-1) and CD86 (B7-2) (3). Two RNA splice variants exist for this molecule, differing only in the cytoplasmic domain (4). Blockade of the CD278-CD275 interaction in mice improves allograft survival (6) and reduces EAE (7).
Applications
Suitable for use in ELISA and Flow Cytometry. Other applications not tested.
Recommended Dilution
Optimal dilutions to be determined by the researcher.
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Immunogen
Recombinant corresponding to human Raji cells CD275-muIg
Form
Supplied as liquid in PBS, 5% Glycerol, 0.2% BSA, 0.04% sodium azide. Labeled with Biotin.
Specificity
Recognizes recombinant human CD275 and cell surface CD275 on Raji cells. It does not block the interaction between recombinant CD278 and CD275.|
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Beier, K.C., R.A. Kroczek, et al. 2000, Eur J Immunol. 30(12):3707-3717, 2. Riley, J.L., C.H. June, et al. 2001, J. Immunol. 166: 4943-4948, 3. Ling, V., M. Collins, et al. 2000, J. Immunol. 164: 1653-1657, 4. Ling, V., M. Collins, et al. 2001, J. Immunol. 166: 7300-7308, 5. K.C. Beier, et al, (2000) Eur J Immunol 30: 3707-3717, 6. E. Ozkaynak, et al, (2001) Nat Immunol 2: 591-596, 7. J.B. Rottman, et al, (2001) Nat Immunol 2: 605-611.USBio References
No references available